Perfusion Medical, LLC
Perfusion Medical, LLC, based in Herndon, VA, is pioneering the development of PM-208, a novel intravenous therapeutic designed to treat hemorrhagic shock and other ischemic conditions by rapidly restoring capillary blood flow to vital organs. Backed by over $19 million in Department of Defense funding, the drug aims to improve survival outcomes significantly, as evidenced by numerous studies from leading research institutions.
The primary mechanism of PM-208 involves enhancing tissue perfusion to enable oxygen delivery to oxygen-deprived tissues, countering the damaging effects of severe hypovolemic shock. As an investigational drug, PM-208 is currently undergoing development and has not yet been approved by the U.S. Food and Drug Administration.
Generated from the website
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.
